Why do so many cancers resist treatment — even when patients receive the strongest chemotherapy available?

In this episode, Dr. Dino Prato, founder of Envita Medical Centers, explains the “Great Wall of Cancer”: a fibrous stromal barrier that surrounds many tumors. This wall blocks chemotherapy, immunotherapy, and even the body’s own immune system from reaching the cancer.

Dr. Prato discusses how this barrier forms, why it accelerates metastasis in cancers like pancreatic, breast, stomach, colorectal, and head and neck cancers, and how Envita uses advanced testing to identify and measure it.

🎯 What You’ll Learn in This Episode:

• Why IV chemotherapy often delivers less than 5% of the drug to the tumor
• How stromal barriers weaken immune cells and push cancer to spread
• The role of spatial biology, molecular profiling, and precision testing in mapping tumor defenses
• How interventional radiology delivers medicine directly inside tumors using tiny catheters
• Why CIPI (Chemo-Immuno-Precision Injection) improves outcomes and activates the immune system
• A real case study where stage IV neuroendocrine carcinoma was successfully treated with this method

📊 In published outcomes, patients receiving these precision approaches saw significant improvements in survival and quality of life compared to standard treatments.*
*(See Outcomes Disclaimer Below)

“Cancer may build a wall — but precision oncology helps break it down.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

Are we really curing cancer… or just managing it for a little longer?

In this compelling episode, Dr. Dino Prato, founder of Envita Medical Centers, reveals the uncomfortable truth behind many FDA-approved cancer drugs: they often provide only 2–3 months of life extension, with little to no improvement in quality of life.

🎯 What You’ll Learn:

• Why many cancer drugs are approved without long-term survival data
• The problem with “Fast Track” approvals and tumor shrinkage as a success metric
• How precision oncology uses multi-omics (RNA, DNA, immune, spatial biology) to guide care
• The difference between managing tumors and striving for durable remission
• How adaptive targeting, microdosing, and interventional delivery aim to reduce resistance and increase response
• What real-time biomarkers (ctDNA, immune signals, tumor microenvironment) tell us about treatment progress

📊 According to Envita’s data, patients mapped with this precision model show improved outcomes, better quality of life, and fewer side effects compared to conventional care — all without relying on “trial and error.”*
*(See Outcomes Disclaimer Below)

“Cancer treatment should aim for long-term remission — not just short-term control.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

Do alternative cancer treatments really work? The answer: sometimes — but only if they’re targeted to your unique cancer.

In this episode, Dr. Dino Prato, founder of Envita Medical Centers, explains why integrative tools like high-dose vitamin C, ozone therapy, methylene blue, ivermectin, and mebendazole can be powerful — but not when they’re given the same way to every patient.

Dr. Prato breaks down how cancer’s biology — from oxygen levels to immune signaling — determines whether these therapies succeed or fail. He shows why adding oxygen support, blocking drug-resistance pumps, or stopping tumor blood supply can enhance chemo only when matched to the right molecular targets.

🎯 What You’ll Learn in This Episode:

• Why “one-size-fits-all” integrative care often fails patients
• How oxygen plays a critical role in tumor growth and resistance
• The science behind high-dose vitamin C, ozone therapy, methylene blue, ivermectin, and mebendazole
• Why combinations of conventional + integrative therapies can be more effective
• The importance of transcriptomics, immune profiling, and tumor microenvironment testing
• Why data-driven targeting beats dogma in both conventional and alternative medicine
• In our experience, patients see the best outcomes when integrative therapies are customized using precision oncology testing — not applied as blanket treatments.

“Alternative treatments can help — but only when guided by data, not guesswork.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493